Abstract
Background: Prescription omega-3 acid ethyl esters (P-OM3) plus simvastatin 20 and 40 mg/day improves lipids in subjects with mixed dyslipidemia, but no previous studies have examined P-OM3 with the maximum prescribed dose of simvastatin (80 mg). Objective: To assess the effects of P-OM3 + simvastatin 80 mg versus P-OM3 + simvastatin 20 mg or placebo + simvastatin 20 mg on non-high-density lipoprotein cholesterol (non-HDL-C) and other lipid concentrations. Methods: Subjects with mixed dyslipidemia who had completed a 12-week double-blind crossover study of simvastatin 20 mg/day + either placebo or P-OM3 4 g/day were enrolled. An analysis (n = 14) was performed following the first six weeks of the extension, during which all subjects received open-label P-OM3 + open-label simvastatin 80 mg/day. Results: P-OM3 + simvastatin 80 mg resulted in significantly larger reductions from baseline (P <.05 for all) versus P-OM3 + simvastatin 20 mg and placebo + simvastatin 20 mg, respectively, for non-HDL-C (-51.0%, -40.8%, -34.9%), low-density lipoprotein cholesterol (-48.0%, -35.5%, -38.0%), total cholesterol (TC) (-42.6%, -31.9%, -27.1%), the TC/HDL-C ratio (-52.9%, -44.3%, -36.2%), and apolipoprotein B (-42.6%, -32.6%, -30.5%). P-OM3 + simvastatin (80- and 20-mg doses, respectively) resulted in significantly larger changes from baseline (P
| Original language | English (US) |
|---|---|
| Pages (from-to) | 33-38 |
| Number of pages | 6 |
| Journal | Journal of Clinical Lipidology |
| Volume | 3 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2009 |
| Externally published | Yes |
Fingerprint
Keywords
- Dyslipidemia
- Hypercholesterolemia
- Omega-3 fatty acids
- Statins
- Triglycerides
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
- Nutrition and Dietetics
Cite this
Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg : effects in mixed dyslipidemia. / Maki, Kevin C.; Lubin, Barry C.; Reeves, Matthew S.; Dicklin, Mary R.; Harris, William.
In: Journal of Clinical Lipidology, Vol. 3, No. 1, 02.2009, p. 33-38.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg
T2 - effects in mixed dyslipidemia
AU - Maki, Kevin C.
AU - Lubin, Barry C.
AU - Reeves, Matthew S.
AU - Dicklin, Mary R.
AU - Harris, William
PY - 2009/2
Y1 - 2009/2
N2 - Background: Prescription omega-3 acid ethyl esters (P-OM3) plus simvastatin 20 and 40 mg/day improves lipids in subjects with mixed dyslipidemia, but no previous studies have examined P-OM3 with the maximum prescribed dose of simvastatin (80 mg). Objective: To assess the effects of P-OM3 + simvastatin 80 mg versus P-OM3 + simvastatin 20 mg or placebo + simvastatin 20 mg on non-high-density lipoprotein cholesterol (non-HDL-C) and other lipid concentrations. Methods: Subjects with mixed dyslipidemia who had completed a 12-week double-blind crossover study of simvastatin 20 mg/day + either placebo or P-OM3 4 g/day were enrolled. An analysis (n = 14) was performed following the first six weeks of the extension, during which all subjects received open-label P-OM3 + open-label simvastatin 80 mg/day. Results: P-OM3 + simvastatin 80 mg resulted in significantly larger reductions from baseline (P <.05 for all) versus P-OM3 + simvastatin 20 mg and placebo + simvastatin 20 mg, respectively, for non-HDL-C (-51.0%, -40.8%, -34.9%), low-density lipoprotein cholesterol (-48.0%, -35.5%, -38.0%), total cholesterol (TC) (-42.6%, -31.9%, -27.1%), the TC/HDL-C ratio (-52.9%, -44.3%, -36.2%), and apolipoprotein B (-42.6%, -32.6%, -30.5%). P-OM3 + simvastatin (80- and 20-mg doses, respectively) resulted in significantly larger changes from baseline (P
AB - Background: Prescription omega-3 acid ethyl esters (P-OM3) plus simvastatin 20 and 40 mg/day improves lipids in subjects with mixed dyslipidemia, but no previous studies have examined P-OM3 with the maximum prescribed dose of simvastatin (80 mg). Objective: To assess the effects of P-OM3 + simvastatin 80 mg versus P-OM3 + simvastatin 20 mg or placebo + simvastatin 20 mg on non-high-density lipoprotein cholesterol (non-HDL-C) and other lipid concentrations. Methods: Subjects with mixed dyslipidemia who had completed a 12-week double-blind crossover study of simvastatin 20 mg/day + either placebo or P-OM3 4 g/day were enrolled. An analysis (n = 14) was performed following the first six weeks of the extension, during which all subjects received open-label P-OM3 + open-label simvastatin 80 mg/day. Results: P-OM3 + simvastatin 80 mg resulted in significantly larger reductions from baseline (P <.05 for all) versus P-OM3 + simvastatin 20 mg and placebo + simvastatin 20 mg, respectively, for non-HDL-C (-51.0%, -40.8%, -34.9%), low-density lipoprotein cholesterol (-48.0%, -35.5%, -38.0%), total cholesterol (TC) (-42.6%, -31.9%, -27.1%), the TC/HDL-C ratio (-52.9%, -44.3%, -36.2%), and apolipoprotein B (-42.6%, -32.6%, -30.5%). P-OM3 + simvastatin (80- and 20-mg doses, respectively) resulted in significantly larger changes from baseline (P
KW - Dyslipidemia
KW - Hypercholesterolemia
KW - Omega-3 fatty acids
KW - Statins
KW - Triglycerides
UR - http://www.scopus.com/inward/record.url?scp=59249107912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59249107912&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2008.12.007
DO - 10.1016/j.jacl.2008.12.007
M3 - Article
VL - 3
SP - 33
EP - 38
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
SN - 1933-2874
IS - 1
ER -